Low-level Viremia in Treated HIV-1 Infected Patients: Advances and Challenges-Reference-Cited by-全球学者库

Low-level Viremia in Treated HIV-1 Infected Patients: Advances and Challenges

Published:2022-03 Issue:2 Volume:20 Page:111-119
ISSN:1570-162X
Container-title:Current HIV Research
language:en
Short-container-title:CHR

Author:

Wu Hao¹,Dai Lili²,Bai Ruojing¹,Lv Shiyun²

Affiliation:

1. Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China

2. Travel Clinic, Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China

Abstract

Abstract: Antiretroviral therapy (ART) can effectively suppress HIV-1 replication, improving quality of life and restoring the lifespan of persons living with HIV (PLWH) to near-normal levels. However, after standardized ART, a low level of HIV-1 RNA, i.e., low-level viremia (LLV), may still be identified in 3% to 10% of the patients. LLV is capable of impacting the immunological and clinical outcomes of patients and serves as a risk factor for transmission. The underlying mechanism of LLV is not yet certain, and the effects of LLV on patient outcomes remain under evaluation. Understanding LLV will allow effective prevention and control strategies to be designed for the benefit of PLWH.

Funder

National 13th Five-Year Grand Program on Key Infectious Disease Control

Beijing Municipal of Science and Technology Major Project

Beijing Natural Science Foundation

Publisher

Bentham Science Publishers Ltd.

Subject

Virology,Infectious Diseases

Reference75 articles.

1. Saag M.S.; Gandhi R.T.; Hoy J.F.; Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel. JAMA 2020,324(16),1651-1669

2. Santoro M.M.; Fabeni L.; Armenia D.; Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis 2014,58(8),1156-1164

3. Havlir D.V.; Bassett R.; Levitan D.; Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA 2001,286(2),171-179

4. Young J.; Rickenbach M.; Calmy A.; Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infect Dis 2015,15(1),382

5. Hofstra L.M.; Mudrikova T.; Stam A.J.; Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients. PLoS One 2014,9(10)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical significance and management of low‐level HIV viremia in the era of integrase strand transfer inhibitors;HIV Medicine;2023-11-22

2. Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case–Control Study;AIDS Research and Human Retroviruses;2023-07-14

3. HIV Tissue Reservoirs: Current Advances in Research;AIDS Patient Care and STDs;2023-06-01

4. The virological consequences of low-level viraemia;The Lancet Global Health;2022-12